Skip to main content

For US Healthcare Professionals

Other Medications


only SGLT2 inhibitor
no dose adjustment needed
in patients
with eGFR ≥45 mL/min/1.73 m2

10 MG
The recommended dose for JARDIANCE is 10 mg once daily
25 MG
In patients who tolerate JARDIANCE 10 mg, the dose can
be increased to 25 mg once daily
JARDIANCE is taken orally with or without food in the morning
  • In patients with volume depletion, correcting this condition prior to initiation of JARDIANCE is recommended
  • Dosing in patients with renal impairment:
    • Assessment of renal function is recommended prior to initiation of JARDIANCE and periodically thereafter
    • Should not be initiated if eGFR is <45 mL/min/1.73 m2
    • Should be discontinued if eGFR is persistently <45 mL/min/1.73 m2
    • Reduction in risk of CV death was consistently observed among patients, including those with eGFR <60 mL/min/1.73 m2
  • A lower dose of insulin or insulin secretagogues (eg, sulfonylureas) may be required to reduce the risk of hypoglycemia when JARDIANCE is used in combination with these agents
  • JARDIANCE is contraindicated in patients with a history of serious hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, severe renal impairment, end-stage renal disease, or dialysis

CV=cardiovascular; eGFR=estimated glomerular filtration rate; SGLT2=sodium glucose co-transporter-2.

You are now leaving a Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Lilly USA, LLC (Lilly) site. BIPI and Lilly are not responsible for the way information is processed by sites linked to this one. Please review those sites' privacy policies and terms of use to understand how your information will be processed. Linking to any other site is at your own risk.

OK Cancel

Click below to explore other medication options